Novartis’s Alcon introduces new innovations in cataract surgery at ESCRS 2017 annual congress

Alcon, a division of Novartis, will introduce Clareon, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS) congress taking place October 7 – 11 in Lisbon, Portugal.

Alcon said that it will deliver an extensive scientific and educational program including 18 accepted abstracts and more than 10 satellite events covering its latest innovations in cataract, refractive and glaucoma surgery.

 “We are proud to deliver on our commitment to bring innovations to the surgical community, and Clareon is one of the biggest breakthroughs in the IOL space,” said Mike Ball, Chief Executive Officer, Alcon. “This is a great year for Alcon as we celebrate many important milestones – from fulfilling our mission to help people see better by enhancing and transforming the way surgeons treat cataracts through innovations like Clareon, to marking the 100 millionth implant of our flagship AcrySof lenses.”

 Alcon’s full scientific and educational program includes symposia, presentations and stand-alone events, highlighting the Clareon monofocal IOL and its novel delivery system, and the benefits of treating concomitant visual conditions such as astigmatism, presbyopia and glaucoma along with cataracts using the AcrySof family of IOLs and the CyPass Micro-Stent. 

 As part of the ESCRS Glaucoma scientific program, further analysis of the COMPASS and CyCLE clinical studies on the CyPass Micro-Stent will be presented. The CyPass Micro-Stent is a minimally invasive glaucoma surgical (MIGS) device, indicated for the treatment of patients with mild-to-moderate primary open-angle glaucoma in conjunction with cataract surgery, or as a standalone procedure in patients with primary open-angle glaucoma who have failed previous medical treatments.

Recently launched in European markets, CyPass Micro-Stent is the first MIGS device designed to be implanted in the supraciliary space, utilizing the same outflow pathway as first-line prostaglandin analog medications and providing an additional option to meet the needs of millions of glaucoma patients.